Hau, Peter and Baumgart, Ulrike and Pfeifer, Katharina and Bock, Anne and Jauch, Tanya and Dietrich, Joerg and Fabel, Klaus and Grauer, Oliver and Wismeth, Caecilia and Klinkhammer-Schalke, Monika and Allgaeuer, Michael and Schuierer, Gerhard and Koch, Horst and Schlaier, Juergen and Brawanski, Alexander and Bogdahn, Ulrich and Steinbrecher, A (2003) Salvage therapy in patients with glioblastoma - Is there any benefit? CANCER, 98 (12). pp. 2678-2686. ISSN 0008-543X
Full text not available from this repository.Abstract
BACKGROUND. Survival after first-line therapy is poor for patients with glioblastoma. The role of second-line treatment for recurrent disease is controversial. The authors studied the outcome in a subset of patients with glioblastoma who were selected for an aggressive reintervention strategy at the time of progression. Their objectives were to improve patients' overall survival with sustained quality of life and to make comparisons with overall survival in unselected patients. METHODS. overall, 168 patients were eligible for retrospective analysis. Ninety patients received specific therapy for disease recurrence (reintervention group) by specific criteria. RESULTS. in the reintervention group, promising median overall survival (mOS) results after diagnosis (61.5 weeks) and progression (33 weeks) were obtained. The progression-free survival (PFS) rate at 12 months and the overall survival rate were superior in the reintervention group (71% at 12 months and 32% at 24 months). compared with the total cohort (45% and 20%, respectively) and the standard group (15% and 5%, respectively). A matched-pair analysis (n = 46 in each group), with an mOS period of 65.5 versus 28.5 weeks, confirmed these data. Quality of life was stable or slightly improved during reinterventions in a subset of patients treated within clinical studies. CONCLUSIONS. The majority of patients in the current series were treated with a reintervention strategy, which had an impact on PFS and mOS. A second resection, focal radiotherapy (in selected cases), and additional chemotherapeutic regimens should be considered for patients with recurrent glioblastoma. (D 2003 American Cancer Society.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | MALIGNANT GLIOMA; PHASE-II; CLINICAL-TRIALS; PCV CHEMOTHERAPY; MULTIFORME; TEMOZOLOMIDE; ASTROCYTOMA; SURVIVAL; CRITERIA; RELAPSE; glioblastoma; disease recurrence; salvage therapy reintervention |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie Medicine > Zentren des Universitätsklinikums Regensburg > Zentrum für Hirntumore (ZHT) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 16 Aug 2021 04:59 |
| Last Modified: | 16 Aug 2021 04:59 |
| URI: | https://pred.uni-regensburg.de/id/eprint/38309 |
Actions (login required)
 |
View Item |
